Summary by Moomoo AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the approval to commence a Phase I/IIa clinical trial for its drug candidate CMND-100, aimed at treating Alcohol Use Disorder (AUD). The approval was granted by the Ministry of Health of Israel and was publicized on February 23, 2024. CMND-100 is an oral capsule based on the proprietary molecule MEAI (5-methoxy-2-aminoindane), which is non-hallucinogenic and has shown potential in reducing the desire for alcohol consumption. The clinical trial will assess the tolerability, safety, and pharmacokinetics of CMND-100 in both healthy volunteers and AUD subjects, with a secondary focus on the drug's efficacy in reducing drinking patterns and cravings. The study will be led by Prof...Show More